Lipid changes after interleukin-6 blockade in rheumatoid arthritis: beyond cholesterol elevation toward hepatic inflammatory-lipoprotein remodeling.

Rheumatoid arthritis is associated with excess cardiovascular morbidity and mortality despite the frequent presence of relatively low circulating lipid levels during active disease, a phenomenon commonly described as the lipid paradox. Interleukin-6 is central to this paradox because it links synovial inflammation with hepatic acute-phase responses, lipoprotein remodeling, thromboinflammatory pathways, and vascular injury. In this narrative review, we examine how IL-6 blockade reshapes the interpretation of lipid changes in rheumatoid arthritis and whether post-treatment cholesterol elevation should be viewed as isolated metabolic harm or as part of a broader process of hepatic inflammatory-lipoprotein remodeling. Mechanistic and translational evidence suggests, but does not yet prove, that active rheumatoid arthritis is characterized not only by reduced lipid concentrations, but also by dysfunctional high-density lipoprotein, oxidative lipoprotein modification, increased serum amyloid A loading, and vascular inflammation. After IL-6 pathway inhibition, particularly with tocilizumab and sarilumab, total cholesterol and low-density lipoprotein cholesterol often increase early; however, these changes may occur alongside reductions in C-reactive protein, serum amyloid A, lipoprotein(a), fibrinogen, and D-dimers, as well as selected improvements in lipoprotein function. Current hard cardiovascular outcome data generally support cardiovascular neutrality rather than a clear increase in major adverse cardiovascular events, although uncertainty remains for specific outcomes, vascular territories, and patient subgroups. Overall, lipid elevation after IL-6 blockade should prompt contextual cardiovascular risk refinement rather than reflexive interpretation as isolated cholesterol-mediated harm.